Reducing drug-related problems in hospitalized pediatric cancer patients through clinical pharmacist interventions: An interventional study from Turkey

Le résumé fourni par la source

Introduction: Clinical pharmacists play a vital role in reviewing anticancer regimens, dose calculations, managing drug-related problems, and monitoring adverse drug reactions. The aim of this study was to identify, classify and reduce drug-related problems in patients with neoplastic disease hospitalized in the pediatric hematology-oncology clinic. Methods: The study was a prospective, interventional study consisting of observation and intervention periods conducted for five months, from April 2024 to August 2024. During the intervention period of the study, clinical pharmacist recommendations for drug-related problems were presented to the healthcare team. Drug-related problems was used in Pharmaceutical Care Network Version 9.1 and were classified according to their clinical significance. Results: A total of 80 patients were included in the study. The median (interquartile range) age of all patients was 7.5 years (4-12.75) and 61.3% were boy. The most common malignancies are acute lymphoblastic leukemia (32.5%) and medulloblastoma (10%). A total of 457 drug-related problems were detected in all periods, 147 of the 457 drug-related problems were related to ‘‘not clinically significant’’ drug-drug interactions. In the intervention period, the frequency of all drug-related problems decreased by 56.3% ( p < 0.001). The most common causes of drug-related problems were drug-drug interactions (47.7%), other causes (13.8%), and indication no treatment (9.1%). During the intervention period, recommendations were made for 66 of the 138 drug-related problems identified, and all of these recommendations (100%) were accepted by physicians. The intervention period recommendations were mostly in the form of drug dose change (35.3%), change in instructions for use (27.4%), drug change (11.77%) and drug paused/stopped (11.77%). 37% of patients who received chemotherapy had adverse events during and after chemotherapy, and during their hospital stay. The most common chemotherapy-related adverse events were leukopenia (20%), lymphopenia (17.5%), and neutropenia (13.8%). Conclusions: A high incidence of drug-related problems was detected in patients with neoplastic disease hospitalized in the pediatric hematology-oncology clinic. All of the clinical pharmacist's recommendations were accepted by the healthcare team.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.